Predictive Oncology (NASDAQ: POAI) is taking a unique approach
to cancer treatment by utilizing its proprietary database of cancer cases using
the proven power of artificial intelligence (“AI”). A recent article discussing
the company reads, “The company works alongside pharmaceutical, diagnostic and
biotechnology industry players to develop highly customizable assessment
methods that can be applied to both individualize current therapies and develop
the next generation of precision therapies, leading to better outcomes for
patients. The company recently announced a corporate name change from Precision
Therapeutics to Predictive Oncology Inc., which reflects its mission and
strategic emphasis. . . . Predictive Oncology seeks to revolutionize the way
cancer is treated for both the patients of today and those of tomorrow. The
company is well positioned to do exactly that as a result of two key assets:
its ability to grow patients’ own tumors in the laboratory and test the tumors’
responses to chemotherapy, together with its existing database of outcome data
cataloguing more than 150,000 tumors and their specific responses to those
chemotherapies.”
To view the full article, visit http://ibn.fm/310FA
About Predictive Oncology Inc.
Predictive Oncology (formerly Precision Therapeutics Inc.)
operates through its three business units: Helomics, TumorGenesis and Skyline
Medical. Helomics applies artificial intelligence to rich data gathered from
patient tumors to both personalize cancer therapies for patients and drive the development
of new targeted therapies in collaborations with pharmaceutical companies.
Helomics’ CLIA-certified lab provides clinical testing that assists oncologists
in individualizing patient-treatment decisions by providing an evidence-based
road map for therapy. In addition to its proprietary precision-oncology
platform, Helomics offers boutique CRO services that leverage its TruTumor,
patient-derived tumor models coupled to a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’
specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a
new rapid approach to growing tumors in the laboratory, which essentially “fools”
cancer cells into thinking they are still growing inside a patient. Its
proprietary Oncology Discovery Technology Platform kits will assist researchers
and clinicians to identify which cancer cells bind to specific biomarkers. Once
the biomarkers are identified, they can be used in TumorGenesis’ Oncology
Capture Technology Platforms, which isolate and help categorize an individual
patient’s heterogeneous tumor samples to enable the development of
patient-specific treatment options. Helomics and TumorGenesis are focused on
ovarian cancer. Predictive Oncology’s Skyline Medical division markets its
patented and FDA-cleared STREAMWAY System, which automates the collection,
measurement and disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and international
divisions. The company has achieved sales in five of the seven continents
through both direct sales and distributor partners. For more information, visit
the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
